Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

472.27 +10.14 (+2.19%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
63 64 Next >
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Vertex Pharmaceuticals Stock Dives After Q2 Earnings, Phase 2 Results For VX-993
Vertex Pharmaceuticals announces financial results for the second quarter after the market close on Monday. Here's a rundown of the report. 
Via Benzinga
Which stocks are moving after the closing bell on Monday?
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Stock Plummets 13% After Discontinuing VX-993 Despite Q2 Earnings Beat
Vertex Q2 2025 earnings beat estimates, but stock dropped 13% after discontinuing acute pain drug VX-993. Focus remains on CF and other key programs. 
Via Chartmill
Topics Earnings
Earnings Scheduled For August 4, 2025
 
Via Benzinga
Vertex Crashes After Pain Drug Flop Outweighs Second-Quarter Beat
Vertex stock crashed late Monday after the company said it wouldn't advance a next-generation pain drug into more testing. 
Via Investor's Business Daily
Topics ETFs
Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q2 Sales Beat Estimates But Stock Drops 13.5%
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 12.1% year on year to $2.96 billion. The company expects the full... 
Via StockStory
Topics Earnings
Vertex Reports Second Quarter 2025 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Pharmaceuticals Likely To Report Q2 Profit; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
 
Via Benzinga
Stock Market Today: US Stocks Likely To Open Higher Despite Weak Jobs Report—Palantir, Vertex Pharma In Focus
US stock futures are up on Monday after ending Friday deep in the red, following a disappointing jobs report by Bureau of Labor Statistics. 
Via Benzinga
What To Expect From Vertex Pharmaceuticals’s (VRTX) Q2 Earnings
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting earnings this Monday after the bell. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence Economy World Trade
3 Unstoppable Stocks to Buy in August
Here are hot stocks to buy in a hot month. 
Via The Motley Fool
Topics Intellectual Property
Here's How Much $1000 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today
 
Via Benzinga
Examining the Future: Vertex Pharmaceuticals's Earnings Outlook
 
Via Benzinga
2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now
These growth stocks have plenty of room to run. 
Via The Motley Fool
The 3 Things That Matter for Vertex Pharmaceuticals Now
Some of these developments could improve the company's prospects. 
Via The Motley Fool
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results
Via The Motley Fool
3 Monster Stocks in the Making to Buy Right Now
Via The Motley Fool
3 Top Growth Stocks to Buy in the Second Half of 2025
Via The Motley Fool
Topics Artificial Intelligence
Here's How Much $1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
 
Via Benzinga
3 Cash-Burning Stocks Walking a Fine Line
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even... 
Via StockStory
Topics Bankruptcy Economy
Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
My 3 Top Stocks to Buy in a Market That's Highly Volatile (Again)
Via The Motley Fool
Topics Artificial Intelligence Energy World Trade
The Best Stocks to Invest $1,000 in Right Now
Via The Motley Fool
Topics Artificial Intelligence
10 Brilliant Growth Stocks to Buy Now and Hold for the Long Term
With just a little bit of a deeper look, these businesses are positioned for long-term growth. 
Via The Motley Fool
Motley Fool Co-Founder David Gardner Reviews Stock Picks
Via The Motley Fool
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
Via Investor Brand Network
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:VRTX),(NASDAQ:IBRX),(NASDAQ:CRSP),(NASDAQ:CTMX) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Stock Market Today: PROK Soars 515% on Surging Volume Amid Clinical Trial Buzz
Via The Motley Fool
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
63 64 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.